Nothing Special   »   [go: up one dir, main page]

BR0314713A - Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias - Google Patents

Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias

Info

Publication number
BR0314713A
BR0314713A BR0314713-4A BR0314713A BR0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A BR 0314713 A BR0314713 A BR 0314713A
Authority
BR
Brazil
Prior art keywords
treatment
reagents
diseases
processes
disorders associated
Prior art date
Application number
BR0314713-4A
Other languages
English (en)
Inventor
Brendan Smith
Jason Fong
Benjamin A Auspitz
M James Nichols
Grant R Zimmermann
Bradley B Brasher
Noah Sachs
Todd W Chappell
Palaniyandi Manivasakam
Curtis Keith
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314713(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BR0314713A publication Critical patent/BR0314713A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSOS E REAGENTES PARA O TRATAMENTO DE DOENçAS E DISTúRBIOS ASSOCIADOS COM NìVEIS AUMENTADOS DE CITOCINAS PRó-INFLAMATóRIAS". A invenção refere-se a um processo para tratar um paciente diagnosticado com, ou em risco de desenvolver um distúrbio imunoinflamatório pela administração de um SSRI ou um análogo ou metabólito do mesmo e, opcionalmente, um corticosteróide ou outro composto ao paciente. A invenção também caracteriza uma composição farmacêutica contendo um SSRI ou análogo ou metabólito do mesmo e um costicoesteróide ou outro composto para o tratamento ou prevenção de um distúrbio imunoinflamatório.
BR0314713-4A 2002-09-24 2003-09-24 Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias BR0314713A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (1)

Publication Number Publication Date
BR0314713A true BR0314713A (pt) 2005-07-26

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314713-4A BR0314713A (pt) 2002-09-24 2003-09-24 Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias

Country Status (12)

Country Link
EP (1) EP1553955A4 (pt)
JP (1) JP2006503905A (pt)
AR (1) AR041386A1 (pt)
AU (1) AU2003299196A1 (pt)
BR (1) BR0314713A (pt)
CA (1) CA2509526A1 (pt)
HR (1) HRP20050355A2 (pt)
IS (1) IS7811A (pt)
MX (1) MXPA05003152A (pt)
NO (1) NO20051669L (pt)
TW (1) TW200422042A (pt)
WO (1) WO2004030618A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.
US20080255074A1 (en) * 2004-11-19 2008-10-16 N.V. Organon Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP5021621B2 (ja) * 2005-04-13 2012-09-12 アスション ファーマ エー／エス 皮膚の結合組織病を治療するためのβ−２アドレナリン受容体作動薬
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
DK2059234T3 (da) * 2006-09-08 2011-11-28 Ore Pharmaceuticals Inc Fremgangsmåde til at lindre inflammation i fordøjelseskanalen
WO2008033754A2 (en) * 2006-09-11 2008-03-20 Duke University Xanthine derivatives in methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
PT117765A (pt) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
ES2259746T3 (es) * 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
ES2146192T1 (es) * 1997-03-18 2000-08-01 Basf Ag Metodo y composiciones para modular la sensibilidad a los corticosteroides.
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
EP1553955A4 (en) 2008-11-05
AU2003299196A1 (en) 2004-04-23
WO2004030618A2 (en) 2004-04-15
TW200422042A (en) 2004-11-01
AR041386A1 (es) 2005-05-18
CA2509526A1 (en) 2004-04-15
EP1553955A2 (en) 2005-07-20
JP2006503905A (ja) 2006-02-02
WO2004030618A3 (en) 2005-04-07
IS7811A (is) 2005-04-19
NO20051669L (no) 2005-06-10
MXPA05003152A (es) 2006-04-27
HRP20050355A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
TW200509958A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE427129T1 (de) Abgabevorrichtung fur arzneimittel
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
NO20062363L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrrelser
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2005079284A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: COMBINATORX, INCORPORATED (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060103181/RJ DE 11/07/2006.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/56; A61P 37/00

Ipc: A61K 31/56 (2011.01), A61P 37/00 (2011.01)

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.